Damiano Paolicelli1, Eleonora Cocco2, Valentina Di Lecce1, Vita Direnzo1, Lucia Moiola3, Roberta Lanzillo4, Paola Perini5, Simona Malucchi6, Giovanna Borriello7, Emilio Portaccio8, Valentina Panetta9, Giuseppe Fenu2, Francesca Sangalli3, Laura Cacciaguerra5, Maria Trojano1. 1. a Department of Basic Medical Sciences, Neurosciences and Sense Organs , University of Bari Aldo Moro , Bari , Italy. 2. b Multiple Sclerosis Centre, Department of Public Health, Clinical Molecular Medicine , University of Cagliari , Cagliari , Italy. 3. c Department of Neurology, San Raffaele Scientific Institute , University of Milan , Milan , Italy. 4. d Department of Neurosciences, Reproductive and Odontostomatological Sciences , Federico II University - School of Medicine , Naples , Italy. 5. e Multiple Sclerosis Centre of the Veneto Region, Department of Neurosciences , University Hospital of Padua , Padua , Italy. 6. f Neurologia 2 - CRESM , A.O.U. San Luigi Gonzaga , Orbassano , Italy. 7. g Multiple Sclerosis Centre, Department of Neurology and Psychiatry, S. Andrea Hospital , Sapienza University , Rome , Italy. 8. h Department of NEUROFARBA , University of Florence , Florence , Italy. 9. i L'altrastatistica srl - Consultancy & Training , Biostatistics office , Rome , Italy.
Abstract
OBJECTIVE: The TRACER multicenter retrospective study aimed to collect data on treatment adherence in a real-life setting, in order to identify predictors of adherence at baseline. METHODS: We recruited 384 relapsing-remitting (RR) multiple sclerosis patients with at least 12 months of use of RebiSmart®. This electronic device records the performed injections and assesses adherence as the percentage of 'not missing doses', through the connection to the iMed database. Subjects with at least 80% of completed doses at the 12 month of therapy were defined 'treatment adherents'. RESULTS: After 12 months, 89.3% of patients were adherent; 93.2% of patients aged 26-40 years at baseline were adherent (vs 79% of the ≤25 and 87.5% of the ≥41 year olds; p = 0.006). Furthermore, 90.5% of patients with a baseline Expanded Disability Status Scale (EDSS) score <4 showed ≥80% adherence (vs 71.4% in those with EDSS score ≥4; p = 0.016). Fifty-four percent of the patients who were not adherent after 3 months were also not adherent after 12 months (OR 16.8; CI 95%:7.1-39.8). CONCLUSIONS: Patients aged 26-40 years and with an EDSS score <4 at baseline were the most adherent. The status of 'treatment adherent' in the first 3 months was predictive of higher adherence in the long term.
OBJECTIVE: The TRACER multicenter retrospective study aimed to collect data on treatment adherence in a real-life setting, in order to identify predictors of adherence at baseline. METHODS: We recruited 384 relapsing-remitting (RR) multiple sclerosispatients with at least 12 months of use of RebiSmart®. This electronic device records the performed injections and assesses adherence as the percentage of 'not missing doses', through the connection to the iMed database. Subjects with at least 80% of completed doses at the 12 month of therapy were defined 'treatment adherents'. RESULTS: After 12 months, 89.3% of patients were adherent; 93.2% of patients aged 26-40 years at baseline were adherent (vs 79% of the ≤25 and 87.5% of the ≥41 year olds; p = 0.006). Furthermore, 90.5% of patients with a baseline Expanded Disability Status Scale (EDSS) score <4 showed ≥80% adherence (vs 71.4% in those with EDSS score ≥4; p = 0.016). Fifty-four percent of the patients who were not adherent after 3 months were also not adherent after 12 months (OR 16.8; CI 95%:7.1-39.8). CONCLUSIONS:Patients aged 26-40 years and with an EDSS score <4 at baseline were the most adherent. The status of 'treatment adherent' in the first 3 months was predictive of higher adherence in the long term.
Authors: A Ghezzi; A Bianchi; D Baroncini; A Bertolotto; S Malucchi; V Bresciamorra; R Lanzillo; N Milani; V Martinelli; F Patti; C Chisari; M Rottoli; M Simone; D Paolicelli; A Visconti Journal: Neurol Sci Date: 2017-08-22 Impact factor: 3.307
Authors: Peter Joseph Jongen; Wim A Lemmens; Erwin L Hoogervorst; Rogier Donders Journal: Health Qual Life Outcomes Date: 2017-03-14 Impact factor: 3.186